JP7244931B2 - シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法 - Google Patents

シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法 Download PDF

Info

Publication number
JP7244931B2
JP7244931B2 JP2020106421A JP2020106421A JP7244931B2 JP 7244931 B2 JP7244931 B2 JP 7244931B2 JP 2020106421 A JP2020106421 A JP 2020106421A JP 2020106421 A JP2020106421 A JP 2020106421A JP 7244931 B2 JP7244931 B2 JP 7244931B2
Authority
JP
Japan
Prior art keywords
darps
synaptic dysfunction
disease
drebrin
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020106421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022001838A5 (https=
JP2022001838A (ja
Inventor
智明 白尾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALZMED, INC.
Original Assignee
ALZMED, INC.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2020106421A priority Critical patent/JP7244931B2/ja
Application filed by ALZMED, INC. filed Critical ALZMED, INC.
Priority to EP21826587.4A priority patent/EP4170032A4/en
Priority to PCT/JP2021/023135 priority patent/WO2021256550A1/ja
Priority to CN202180043301.0A priority patent/CN115702352A/zh
Priority to US18/002,332 priority patent/US20230349925A1/en
Publication of JP2022001838A publication Critical patent/JP2022001838A/ja
Publication of JP2022001838A5 publication Critical patent/JP2022001838A5/ja
Priority to JP2023032921A priority patent/JP7620340B2/ja
Application granted granted Critical
Publication of JP7244931B2 publication Critical patent/JP7244931B2/ja
Priority to JP2024231531A priority patent/JP2025060925A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2020106421A 2020-06-19 2020-06-19 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法 Active JP7244931B2 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2020106421A JP7244931B2 (ja) 2020-06-19 2020-06-19 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
PCT/JP2021/023135 WO2021256550A1 (ja) 2020-06-19 2021-06-18 シナプス機能不全に起因する疾病、又はシナプス機能不全を付随する疾病の判定方法
CN202180043301.0A CN115702352A (zh) 2020-06-19 2021-06-18 因突触功能不全引起的疾病或附带突触功能不全的疾病的判定方法
US18/002,332 US20230349925A1 (en) 2020-06-19 2021-06-18 Method for determining disease caused by synaptic dysfunction or disease accompanied by synaptic dysfunction
EP21826587.4A EP4170032A4 (en) 2020-06-19 2021-06-18 METHOD FOR DETERMINING A DISEASE CAUSED BY SYNAPTIC DYSFUNCTION OR A DISEASE ACCOMPANIED BY SYNAPTIC DYSFUNCTION
JP2023032921A JP7620340B2 (ja) 2020-06-19 2023-03-03 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
JP2024231531A JP2025060925A (ja) 2020-06-19 2024-12-27 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020106421A JP7244931B2 (ja) 2020-06-19 2020-06-19 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023032921A Division JP7620340B2 (ja) 2020-06-19 2023-03-03 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法

Publications (3)

Publication Number Publication Date
JP2022001838A JP2022001838A (ja) 2022-01-06
JP2022001838A5 JP2022001838A5 (https=) 2022-06-14
JP7244931B2 true JP7244931B2 (ja) 2023-03-23

Family

ID=79244367

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020106421A Active JP7244931B2 (ja) 2020-06-19 2020-06-19 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
JP2023032921A Active JP7620340B2 (ja) 2020-06-19 2023-03-03 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
JP2024231531A Pending JP2025060925A (ja) 2020-06-19 2024-12-27 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023032921A Active JP7620340B2 (ja) 2020-06-19 2023-03-03 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
JP2024231531A Pending JP2025060925A (ja) 2020-06-19 2024-12-27 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法

Country Status (5)

Country Link
US (1) US20230349925A1 (https=)
EP (1) EP4170032A4 (https=)
JP (3) JP7244931B2 (https=)
CN (1) CN115702352A (https=)
WO (1) WO2021256550A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4632384A1 (en) * 2022-12-05 2025-10-15 AlzMed, Inc. Method for determining cognitive dysfunction stage
WO2025177848A1 (ja) * 2024-02-22 2025-08-28 アルメッド株式会社 ドレブリン由来のｉＭＡＤＰ、ｉＭＡＤＰを測定する方法及びｉＭＡＤＰの測定用キット

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003180361A (ja) 2001-12-13 2003-07-02 Japan Science & Technology Corp ｓ−ドレブリンＡ
JP4550530B2 (ja) 2004-09-03 2010-09-22 独立行政法人科学技術振興機構 シナプス成熟障害モデル動物
JP4568463B2 (ja) 2001-11-05 2010-10-27 独立行政法人科学技術振興機構 ドレブリンａ発現抑制動物神経細胞及び非ヒトモデル動物
JP2016040540A (ja) 2014-08-13 2016-03-24 国立大学法人群馬大学 ドレブリンａ及びドレブリンｅの特異的定量法
WO2019216345A1 (ja) 2018-05-08 2019-11-14 アルメッド株式会社 ドレブリンに特異的に結合するペプチド、及びそのペプチドを用いたドレブリンの検出方法
WO2020184676A1 (ja) 2019-03-13 2020-09-17 国立大学法人群馬大学 Ｎｍｄａ受容体阻害活性のハイスループット評価方法
JP2021058148A (ja) 2019-10-08 2021-04-15 国立大学法人群馬大学 アルツハイマー病モデル非ヒト動物及びその製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007674A2 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Neuronal and retinal gene expression patterns
WO2016205730A1 (en) * 2015-06-18 2016-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Citrullinated proteins and their breakdown products as tbi biomarkers
JP7111494B2 (ja) 2018-04-05 2022-08-02 グローリー株式会社 光検出センサ、光検出装置、シート類処理装置および光検出方法
CN109490527B (zh) * 2018-11-08 2020-01-21 温州医科大学 Dbn1蛋白在制备神经变性疾病诊断药物中的应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4568463B2 (ja) 2001-11-05 2010-10-27 独立行政法人科学技術振興機構 ドレブリンａ発現抑制動物神経細胞及び非ヒトモデル動物
JP2003180361A (ja) 2001-12-13 2003-07-02 Japan Science & Technology Corp ｓ−ドレブリンＡ
JP4550530B2 (ja) 2004-09-03 2010-09-22 独立行政法人科学技術振興機構 シナプス成熟障害モデル動物
JP2016040540A (ja) 2014-08-13 2016-03-24 国立大学法人群馬大学 ドレブリンａ及びドレブリンｅの特異的定量法
WO2019216345A1 (ja) 2018-05-08 2019-11-14 アルメッド株式会社 ドレブリンに特異的に結合するペプチド、及びそのペプチドを用いたドレブリンの検出方法
WO2020184676A1 (ja) 2019-03-13 2020-09-17 国立大学法人群馬大学 Ｎｍｄａ受容体阻害活性のハイスループット評価方法
JP2021058148A (ja) 2019-10-08 2021-04-15 国立大学法人群馬大学 アルツハイマー病モデル非ヒト動物及びその製造方法

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
K Hatanpaa，immunoreactivity for drebrin, a marker of dendritic plasticity, in human cerebral cortex in normal aging and alzheimer's disease，Abstracts - Society for Neuroscience，1997年，Vol.23 No.1-2，Page.1650 640.20
Ki Shuk Shim，Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer’s disease and Down syndrome，Neuroscience Letters，2002年，Vol.324，Page.209-212
KIMMMO HATANPAA，Loss of proteins regulating synaptic plasticity in normal aging of the human brain and in Alzheimer disease，Journal of Neuropathology and Experimental Neurology，1999年06月，Vol.58 No.6，Page.637-643
L. I. Sinclair，Synaptic protein levels altered in vascular dementia，Neuropathology and Applied Neurobiology，2015年04月23日，Vol.41 No.4，Page.533-543
Scott E. Counts，Differential Expression of Synaptic Proteins in the Frontal and Temporal Cortex of Elderly Subjects With Mild Cognitive Impairment，J Neuropathol Exp Neurol，2006年06月，Vol.65 No.6，Page.592-601
Shoji Mikio，Disturbance of cytoskeletal actinin Alzheimer's disease，Journal of Pharmacological Sciences，2007年02月28日，Vol.103 No.Supplement 1，Page.46P
SONG M，Migrating neuronal precursors in adult rat brain express drebrin E but not drebrin A，神経化学，2004年08月10日，Vol.43 No.2/3，Page.536 P3-107
Y. Harigaya，Disappearance of Actin-Binding Protein, Drebrin, From Hippocampal Synapses in Alzheimer’s Disease，Journal of Neuroscience Research，1996年，Vol.43 No.1，Page.87-92
Yasuda Hiroki，Drebrin Isoforms Critically Regulate NMDAR- and mGluR-Dependent LTD Induction，Frontiers in Cellular Neuroscience，Vol.12，2018年10月08日，Page.330
児島伸彦，神経疾患とドレブリン，Clinical Neuroscience，2006年12月01日，Vol.24 No.12，Page.1392-1393
小島伸彦，シナプスの構造可塑性制御因子ドレブリン，工業技術，東洋大学工業技術研究所，2018年，Vol.40，Page.69-73，http://id.nii.ac.jp/1060/00009584/
忘却の脳内メカニズムの鍵を発見 ～記憶・学習障害の治療法開発への新たな期待～，2018年10月05日，https://www.toyo.ac.jp/uploaded/attachment/117655.pdf
白尾智明，ドレブリンの発見から医療応用まで ～脳科学の面白さ～，群馬大学大学院医学系研究科 医科学専攻基礎・基盤医学領域神経薬理学講座神経薬理学分野，2020年02月06日，http://neuro.dept.med.gunma-u.ac.jp/wp-content/uploads/2020/02/333865b6454b0914d0af5828cea802ff.pdf
白尾智明，機能と分子基盤 樹状突起棘(スパイン)のアクチンフィラメントと微小管，Clinical Neuroscience，2013年12月01日，Vol.31 No.12，Page.1392-1395

Also Published As

Publication number Publication date
US20230349925A1 (en) 2023-11-02
EP4170032A4 (en) 2024-12-18
JP2023075214A (ja) 2023-05-30
WO2021256550A1 (ja) 2021-12-23
EP4170032A1 (en) 2023-04-26
JP7620340B2 (ja) 2025-01-23
CN115702352A (zh) 2023-02-14
JP2025060925A (ja) 2025-04-10
JP2022001838A (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
Koper et al. Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer’s disease
Majbour et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
Zetterberg Blood-based biomarkers for Alzheimer’s disease—An update
Mollenhauer et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
AU2015212908B2 (en) Biomarker and methods for early diagnosis of Alzheimer's disease
McAleese et al. Extravascular fibrinogen in the white matter of Alzheimer’s disease and normal aged brains: implications for fibrinogen as a biomarker for Alzheimer’s disease
JP2025060925A (ja) シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
Liu et al. Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment
Camporesi et al. Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
Kac et al. Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology
WO2011005628A1 (en) Detection of neurodegenerative disease
Lee et al. Multi‐proteomic analyses of 5xFAD mice reveal new molecular signatures of early‐stage Alzheimer's disease
TWI822802B (zh) 腎病變蛋白生物標記及其應用
JP4933159B2 (ja) アルツハイマー病の診断方法
WO2012015050A1 (ja) アミロイドβペプチド蓄積を伴う疾患の診断の為の可溶型アミロイドβ前駆体タンパク質７７０β切断産物の検出方法
JP7307479B2 (ja) ＩｇＡ腎症診断用キット
US9618522B2 (en) Diagnostic testing in dementia and methods related thereto
US20250306040A1 (en) Methods and kits for detection of amylin-beta amyloid co-aggregation
Blennow Development of Fluid Biomarkers for Alzheimer’s Disease
JP2025073338A (ja) アルツハイマー病罹患者の認知機能障害の進行リスク又は発症リスクの検査方法、及びアルツハイマー病の検査方法
Cao et al. Histopathological Analysis of Cerebral Microvasculature Pathology with Alzheimer’s Disease Neuropathological Changes: An Autopsy Study
Gawor et al. Amygdala-predominant α-synuclein pathology exacerbates hippocampal neuron loss in Alzheimer’s disease
Gawor et al. BRAIN COMMUNICATIONS
JP6908810B2 (ja) ４リピートタウの質的違いを検出する特異的結合試薬、これを用いた検査方法、検査キット、及び医薬のスクリーニング方法
Shinohara et al. Characterization of Tau ELISAs for Evaluating Tau Accumulation in the Brains With Alzheimer’s Disease

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220411

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220516

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230303

R150 Certificate of patent or registration of utility model

Ref document number: 7244931

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250